Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

17.05.21	Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial (GlobeNewswire)
06.05.21	Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research (GlobeNewswire)
30.04.21	Annual General Meeting of April 30, 2021 (GlobeNewswire)
28.04.21	Sanofi Stock Up On Q1 Business Earnings; Backs FY21 View (RTTNews)
28.04.21	Sanofi Q1 Profit Down - Quick Facts (RTTNews)
26.04.21	Sanofi To Help Manufacture Up To 200 Mln Doses Of Moderna's Vaccine In U.S. (RTTNews)
26.04.21	AZN : Phase III Trial On Nirsevimab Meets Primary Endpoint In Lower Respiratory Tract Infections (RTTNews)
26.04.21	Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial (GlobeNewswire)
23.04.21	Sanofi Says Dupixent Trials Reinforce Long-term Safety In Patients With Atopic Dermatitis (RTTNews)
23.04.21	New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years (GlobeNewswire)
19.04.21	Evotec Reaches Licensing And Master Service Agreement With Kazia On Oncology (RTTNews)
19.04.21	Sanofi : EC Okays Second Indication Of Sarclisa For Relapsed Multiple Myeloma (RTTNews)
19.04.21	European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma (GlobeNewswire)
13.04.21	Sanofi Declares Offer For Kiadis Unconditional; All Offer Conditions Now Satisfied (RTTNews)
12.04.21	Sanofi To Build EUR 400 Mln Vaccine Production Site In Singapore (RTTNews)
12.04.21	Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities (GlobeNewswire)
09.04.21	Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas (GlobeNewswire)
09.04.21	Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2 (GlobeNewswire)
07.04.21	Sanofi To Provide Essential Medicines For Patients In Lower Income Countries (RTTNews)
07.04.21	Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines (GlobeNewswire)
31.03.21	FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (GlobeNewswire)
31.03.21	Sanofi To Invest More Than EUR 600 Mln To Build New Vaccine Facility In Toronto (RTTNews)
31.03.21	Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine (GlobeNewswire)
19.03.21	Oxford Biomedica: Sanofi To Terminate Collaboration And License Deal In Haemophilia Gene Therapy (RTTNews)
19.03.21	Availability of the Q1 2021 Memorandum for modelling purposes (GlobeNewswire)
16.03.21	EMA Safety Committee To Further Review AZD1222, RUBY Sparkles, DMD Trial Data Fails To Ignite SLDB (RTTNews)
15.03.21	Sanofi : Phase 3 Trial Of Libtayo In Advanced Cervical Cancer Stopped Early For Positive Result (RTTNews)
15.03.21	Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival (GlobeNewswire)
12.03.21	Sanofi, Translate Bio Start Phase 1/2 Clinical Trial Of MRNA COVID-19 Vaccine Candidate (RTTNews)
12.03.21	Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate (GlobeNewswire)
04.03.21	Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report (GlobeNewswire)
04.03.21	Sanofi : FDA Accepts Dupixent For Review In Children With Moderate-to-severe Asthma (RTTNews)
04.03.21	FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma (GlobeNewswire)
03.03.21	Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members (GlobeNewswire)
22.02.21	FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50% (GlobeNewswire)
22.02.21	Sanofi, GSK To Refine Antigen Formulation Of COVID-19 Vaccine Based On Initial Phase 1/2 Study (RTTNews)
22.02.21	Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate (GlobeNewswire)
16.02.21	Bristol-Myers, Sanofi Ordered To Pay $834 Mln Over Plavix In Hawaii (RTTNews)
12.02.21	Sanofi Launches Recommended Cash Offer For Kiadis (RTTNews)
12.02.21	The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50% (GlobeNewswire)
11.02.21	BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod (RTTNews)
09.02.21	FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma (GlobeNewswire)
05.02.21	Sanofi Stock Up On Q4 Profit, Positive FY21 Earnings View (RTTNews)
05.02.21	Sanofi Increases Cost Savings Target - Quick Facts (RTTNews)
05.02.21	Sanofi Q4 Business EPS Up 9.8% At CER; Sales Growth At 4.2% (RTTNews)
05.02.21	Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology (GlobeNewswire)
25.01.21	Sanofi, Capgemini, Generali, Orange Join To Create Digital Ecosystem In France (RTTNews)
21.01.21	Beximco Pharma To Acquire Majority Stake In Sanofi Bangladesh - Quick Facts (RTTNews)
19.01.21	Sanofi : U.K. Grants Promising Innovative Medicine Designation To Nirsevimab (RTTNews)
12.01.21	SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Handel in Europa: STOXX 50 schliesst im Minus

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten

20.12.24

SPI-Handel aktuell: SPI zum Handelsende leichter